肝癌电子杂志 ›› 2021, Vol. 8 ›› Issue (3): 35-40.
曹胤, 王忠夏, 江春平
收稿日期:
2021-05-21
出版日期:
2021-09-30
发布日期:
2021-10-20
通讯作者:
江春平,E-mail: chunpingjiang@163.com
作者简介:
曹胤 硕士研究生,南京大学医学院附属鼓楼医院, 肝胆外科
基金资助:
Cao Yin, Wang Zhongxia, Jiang Chunping
Received:
2021-05-21
Online:
2021-09-30
Published:
2021-10-20
摘要: 肝移植是肝细胞癌重要的治疗方式,但术后的复发率仍偏高。全身炎症反应可以通过一些常见的血清学指标包括中性粒细胞、淋巴细胞、血小板、C反应蛋白及以上述因子构建的简单炎症指数来反映。这些炎症相关指数对接受肝移植的肝癌患者预后具有重要预测意义。本文就目前常用的系统性炎症指标如中性粒细胞-淋巴细胞比值、血小板-淋巴细胞比值、淋巴细胞-单核细胞比值、系统性免疫炎症指数、预后营养指数、格拉斯哥预后评分在肝癌肝移植预后中的价值作一综述。
曹胤, 王忠夏, 江春平. 简单炎症相关指数在肝癌肝移植预后预测中的价值[J]. 肝癌电子杂志, 2021, 8(3): 35-40.
Cao Yin, Wang Zhongxia, Jiang Chunping. The prognostic value of simple inflammation-related indexes in predicting liver transplantation for hepatocellular carcinoma[J]. Electronic Journal of Liver Tumor, 2021, 8(3): 35-40.
[1] SCHWARTZ M E, D'AMICO F, VITALE A, et al. Liver transplantation for hepatocellular carcinoma: Are the Milan criteria still valid?[J]. Eur J Surg Oncol, 2008, 34(3): 256-262. [2] JONAS S, BECHSTEIN W O, STEINMÜLLER T, et al. Vascular invasion and histopathologic grading determine outcome after liver transplantation for hepatocellular carcinoma in cirrhosis[J]. Hepatology, 2001, 33(5): 1080-1086. [3] MA Q, LIU W, JIA R, et al.Inflammation-based prognostic system predicts postoperative survival of esophageal carcinoma patients with normal preoperative serum carcinoembryonic antigen and squamous cell carcinoma antigen levels[J]. World J Surg Oncol, 2016, 14: 141. [4] WU X S, SHI L B, LI M L, et al.Evaluation of two inflammation-based prognostic scores in patients with resectable gallbladder carcinoma[J]. Ann Surg Oncol, 2014, 21(2): 449-457. [5] AGOPIAN V G, PETROWSKY H, KALDAS F M, et al.The evolution of liver transplantation during 3 decades: analysis of 5347 consecutive liver transplants at a single center[J]. Ann Surg, 2013, 258(3): 409-421. [6] LU D S, YU N C, RAMAN S S, et al.Percutaneous radiofrequency ablation of hepatocellular carcinoma as a bridge to liver transplantation[J]. Hepatology, 2005, 41(5): 1130-1137. [7] BISHAYEE A.The role of inflammation and liver cancer[J]. Adv Exp Med Biol, 2014, 816: 401-435. [8] LEE F Y, LEE S D, TSAI Y T, et al.Serum C-reactive protein as a serum marker for the diagnosis of hepatocellular carcinoma[J]. Cancer, 1989, 63(8): 1567-1571. [9] GOMEZ D, FARID S, MALIK H Z, et al.Preoperative neutrophil-to-lymphocyte ratio as a prognostic predictor after curative resection for hepatocellular carcinoma[J]. World J Surg, 2008, 32(8): 1757-1762. [10] WANG Y, ATTAR B M, FUENTES H E, et al.Evaluation of the prognostic value of platelet to lymphocyte ratio in patients with hepatocellular carcinoma[J]. J Gastrointest Oncol, 2017, 8(6): 1065-1071. [11] XU Z G, YE C J, LIU L X, et al.The pretransplant neutrophil-lymphocyte ratio as a new prognostic predictor after liver transplantation for hepatocellular cancer: a systematic review and meta-analysis[J]. Biomark Med, 2018, 12(2): 189-199. [12] PROCTOR M J, MORRISON D S, TALWAR D, et al.A comparison of inflammation-based prognostic scores in patients with cancer. A Glasgow Inflammation Outcome Study[J]. Eur J Cancer, 2011, 47(17): 2633-2641. [13] NAJJAR M, AGRAWAL S, EMOND J C, et al.Pretreatment neutrophil-lymphocyte ratio: useful prognostic biomarker in hepatocellular carcinoma[J]. J Hepatocell Carcinoma, 2018, 5: 17-28. [14] PARISI I, TSOCHATZIS E, WIJEWANTHA H, et al.Inflammation-based scores do not predict post-transplant recurrence of hepatocellular carcinoma in patients within Milan criteria[J]. Liver Transpl, 2014, 20(11): 1327-1335. [15] LAI Q, CASTRO SANTA E, RICO JURI J M, et al. Neutrophil and platelet-to-lymphocyte ratio as new predictors of dropout and recurrence after liver transplantation for hepatocellular cancer[J]. Transpl Int, 2014, 27(1): 32-41. [16] ISMAEL M N, FORDE J, MILLA E, et al.Utility of Inflammatory Markers in Predicting Hepatocellular Carcinoma Survival after Liver Transplantation[J]. Biomed Res Int, 2019, 2019: 7284040. [17] HALAZUN K J, HARDY M A, RANA A A, et al.Negative impact of neutrophil-lymphocyte ratio on outcome after liver transplantation for hepatocellular carcinoma[J]. Ann Surg, 2009, 250(1): 141-151. [18] BERTUZZO V R, CESCON M, RAVAIOLI M, et al.Analysis of factors affecting recurrence of hepatocellular carcinoma after liver transplantation with a special focus on inflammation markers[J]. Transplantation, 2011, 91(11): 1279-1285. [19] WANG G Y, YANG Y, LI H, et al.A scoring model based on neutrophil to lymphocyte ratio predicts recurrence of HBV-associated hepatocellular carcinoma after liver transplantation[J]. PLoS One, 2011, 6(9): e25295. [20] MOTOMURA T, SHIRABE K, MANO Y, et al.Neutrophil-lymphocyte ratio reflects hepatocellular carcinoma recurrence after liver transplantation via inflammatory microenvironment[J]. J Hepatol, 2013, 58(1): 58-64. [21] LIMAYE A R, CLARK V, SOLDEVILA-PICO C, et al.Neutrophil-lymphocyte ratio predicts overall and recurrence-free survival after liver transplantation for hepatocellular carcinoma[J]. Hepatol Res, 2013, 43(7): 757-764. [22] XIAO G Q, LIU C, LIU D L, et al.Neutrophil-lymphocyte ratio predicts the prognosis of patients with hepatocellular carcinoma after liver transplantation[J]. World J Gastroenterol, 2013, 19(45): 8398-8407. [23] YOSHIZUMI T, IKEGAMI T, YOSHIYA S, et al.Impact of tumor size, number of tumors and neutrophil-to-lymphocyte ratio in liver transplantation for recurrent hepatocellular carcinoma[J]. Hepatol Res, 2013, 43(7): 709-716. [24] NA G H, KIM D G, HAN J H, et al.Inflammatory markers as selection criteria of hepatocellular carcinoma in living-donor liver transplantation[J]. World J Gastroenterol, 2014, 20(21): 6594-6601. [25] SHINDOH J, SUGAWARA Y, NAGATA R, et al.Evaluation methods for pretransplant oncologic markers and their prognostic impacts in patient undergoing living donor liver transplantation for hepatocellular carcinoma[J]. Transpl Int, 2014, 27(4): 391-398. [26] AGOPIAN V G, HARLANDER-LOCKE M, ZARRINPAR A, et al.A novel prognostic nomogram accurately predicts hepatocellular carcinoma recurrence after liver transplantation: analysis of 865 consecutive liver transplant recipients[J]. J Am Coll Surg, 2015, 220(4): 416-427. [27] WANG W, YE Y, WANG T, et al.Prognostic prediction of male recipients selected for liver transplantation: With special attention to neutrophil to lymphocyte ratio[J]. Hepatol Res, 2016, 46(9): 899-907. [28] HARIMOTO N, YOSHIZUMI T, SHIMAGAKI T, et al.Inflammation-based Prognostic Score in Patients with Living Donor Liver Transplantation for Hepatocellular Carcinoma[J]. Anticancer Res, 2016, 36(10): 5537-5542. [29] REN A, LI Z, ZHANG X, et al.Inflammation-Based Prognostic Scores in Patients with Hepatitis B Virus-Related Hepatocellular Carcinoma After Liver Transplantation[J]. J Hepatocell Carcinoma, 2020, 7: 101-106. [30] KONG W, QU E, SHENG N, et al.Prognostic significance of inflammation-based score in patients with hepatocellular carcinoma after liver transplantation[J]. Eur J Gastroenterol Hepatol, 2021. [31] SVENNEVIG J L, LUNDE O C, HOLTER J, et al.Lymphoid infiltration and prognosis in colorectal carcinoma[J]. Br J Cancer, 1984, 49(3): 375-377. [32] MANO Y, SHIRABE K, YAMASHITA Y, et al.Preoperative neutrophil-to-lymphocyte ratio is a predictor of survival after hepatectomy for hepatocellular carcinoma: a retrospective analysis[J]. Ann Surg, 2013, 258(2): 301-305. [33] POON R T, FAN S T, LO C M, et al.Long-term survival and pattern of recurrence after resection of small hepatocellular carcinoma in patients with preserved liver function: implications for a strategy of salvage transplantation[J]. Ann Surg, 2002, 235(3): 373-382. [34] SCHREIBER R D, OLD L J, SMYTH M J.Cancer immunoediting: integrating immunity's roles in cancer suppression and promotion[J]. Science, 2011, 331(6024): 1565-1570. [35] ZHOU D, LIANG J, XU L I, et al.Derived neutrophil to lymphocyte ratio predicts prognosis for patients with HBV-associated hepatocellular carcinoma following transarterial chemoembolization[J]. Oncol Lett, 2016, 11(5): 2987-2994. [36] XIA W, KE Q, WANG Y, et al.Predictive value of pre-transplant platelet to lymphocyte ratio for hepatocellular carcinoma recurrence after liver transplantation[J]. World J Surg Oncol, 2015, 13: 60. [37] PRAVISANI R, MOCCHEGIANI F, ISOLA M, et al.Postoperative Trends and Prognostic Values of Inflammatory and Nutritional Biomarkers after Liver Transplantation for Hepatocellular Carcinoma[J]. Cancers (Basel), 2021, 13(3). [38] FU H, ZHENG J, CAI J, et al.Systemic Immune-Inflammation Index (SII) is Useful to Predict Survival Outcomes in Patients After Liver Transplantation for Hepatocellular Carcinoma within Hangzhou Criteria[J]. Cell Physiol Biochem, 2018, 47(1): 293-301. [39] LAI Q, MELANDRO F, LARGHI LAUREIRO Z, et al.Platelet-to-lymphocyte ratio in the setting of liver transplantation for hepatocellular cancer: A systematic review and meta-analysis[J]. World J Gastroenterol, 2018, 24(15): 1658-1665. [40] XIA W, KE Q, GUO H, et al.Expansion of the Milan criteria without any sacrifice: combination of the Hangzhou criteria with the pre-transplant platelet-to-lymphocyte ratio[J]. BMC Cancer, 2017, 17(1): 14. [41] CHAN J C, CHAN D L, DIAKOS C I, et al.The Lymphocyte-to-Monocyte Ratio is a Superior Predictor of Overall Survival in Comparison to Established Biomarkers of Resectable Colorectal Cancer[J]. Ann Surg, 2017, 265(3): 539-546. [42] XUE P, HANG J, HUANG W, et al.Validation of Lymphocyte-to-Monocyte Ratio as a Prognostic Factor in Advanced Pancreatic Cancer: An East Asian Cohort Study of 2 Countries[J]. Pancreas, 2017, 46(8): 1011-1017. [43] MANO Y, YOSHIZUMI T, YUGAWA K, et al.Lymphocyte-to-Monocyte Ratio Is a Predictor of Survival After Liver Transplantation for Hepatocellular Carcinoma[J]. Liver Transpl, 2018, 24(11): 1603-1611. [44] MAZZAFERRO V, REGALIA E, DOCI R, et al.Liver transplantation for the treatment of small hepatocellular carcinomas in patients with cirrhosis[J]. N Engl J Med, 1996, 334(11): 693-699. [45] REN A, LI Z, CHENG P, et al.Systemic Immune-Inflammation Index Is a Prognostic Predictor in Patients with Intrahepatic Cholangiocarcinoma Undergoing Liver Transplantation[J]. Mediators Inflamm, 2021, 2021: 6656996. [46] ONODERA T, GOSEKI N, KOSAKI G.[Prognostic nutritional index in gastrointestinal surgery of malnourished cancer patients][J]. Nihon Geka Gakkai Zasshi, 1984, 85(9): 1001-1005. [47] ALVARES-DA-SILVA M R, REVERBEL DA SILVEIRA T. Comparison between handgrip strength, subjective global assessment, and prognostic nutritional index in assessing malnutrition and predicting clinical outcome in cirrhotic outpatients[J]. Nutrition, 2005, 21(2): 113-117. [48] KAWAMURA N, NAKAJIMA H, TAKASHI S I.Administration of granulated BCAA and quality of life[J]. Hepatol Res, 2004, 30s: 42-45. [49] JIANG N, DENG J Y, DING X W, et al.Prognostic nutritional index predicts postoperative complications and long-term outcomes of gastric cancer[J]. World J Gastroenterol, 2014, 20(30): 10537-10544. [50] GENG Y, QI Q, SUN M, et al.Prognostic nutritional index predicts survival and correlates with systemic inflammatory response in advanced pancreatic cancer[J]. Eur J Surg Oncol, 2015, 41(11): 1508-1514. [51] OKAMURA Y, SUGIURA T, ITO T, et al.The optimal cut-off value of the preoperative prognostic nutritional index for the survival differs according to the TNM stage in hepatocellular carcinoma[J]. Surg Today, 2017, 47(8): 986-993. [52] AINO H, SUMIE S, NIIZEKI T, et al.The systemic inflammatory response as a prognostic factor for advanced hepatocellular carcinoma with extrahepatic metastasis[J]. Mol Clin Oncol, 2016, 5(1): 83-88. [53] WANG D, DUAN L, TU Z, et al.The Glasgow Prognostic Score Predicts Response to Chemotherapy in Patients with Metastatic Breast Cancer[J]. Chemotherapy, 2016, 61(4): 217-222. [54] KNIGHT B C, KAUSAR A, MANU M, et al.Evaluation of surgical outcome scores according to ISGPS definitions in patients undergoing pancreatic resection[J]. Dig Surg, 2010, 27(5): 367-374. [55] POLTERAUER S, GRIMM C, SEEBACHER V, et al.The inflammation-based Glasgow Prognostic Score predicts survival in patients with cervical cancer[J]. Int J Gynecol Cancer, 2010, 20(6): 1052-1057. [56] ABE T, TASHIRO H, HATTORI M, et al.Prediction of long-term survival by using the Glasgow Prognostic Score in patients with hepatocellular carcinoma after liver transplantation[J]. Hepatol Res, 2016, 46(7): 622-633. [57] KALTENBORN A, SCHREM H, REICHERT B, et al.The Glasgow Prognostic Score and its variants predict mortality in living donor but not in deceased donor liver transplantation for hepatocellular carcinoma: A double-center validation study[J]. Hepatol Res, 2017, 47(8): 783-792. [58] AGALAR C, EGELI T, UNEK T, et al.The Predictive Ability of the Glasgow Prognostic Score and Variants in Both Deceased Donor and Living Donor Liver Transplantation for Hepatocellular Cancer[J]. Transplant Proc, 2019, 51(4): 1134-1138. |
[1] | 贺强, 周林. 构建以雷帕霉素为主预防肝癌肝移植术后肿瘤复发的综合防治体系[J]. 肝癌电子杂志, 2021, 8(3): 1-7. |
[2] | 姜涛, 潘飞, 陈晴, 黄金灿, 贺强, 郎韧. CYP3A5基因多态性指导肝细胞癌肝移植术后他克莫司个体化用药的临床研究[J]. 肝癌电子杂志, 2021, 8(3): 8-11. |
[3] | 谢炎, 张炜琪, 孙纪三, 蒋文涛. 超米兰标准肝癌肝移植术后肿瘤复发的综合治疗与局部治疗的疗效比较[J]. 肝癌电子杂志, 2021, 8(3): 12-16. |
[4] | 周林, 汪京, 赵阳, 李瀚, 杜国盛, 史宪杰, 贺强, 郎韧. 乏氧诱导因子-1α与肝细胞癌患者预后生存相关性分析[J]. 肝癌电子杂志, 2021, 8(3): 17-25. |
[5] | 吕少诚, 郎韧. 肝移植技术在治疗转移性肝肿瘤中的研究现状[J]. 肝癌电子杂志, 2021, 8(3): 26-29. |
[6] | 熊俊, 万赤丹. 免疫调定点抑制剂在肝癌肝移植患者中的应用[J]. 肝癌电子杂志, 2021, 8(3): 30-34. |
[7] | 林鑫, 肖慜, 李启勇. 肝移植供肝体积评估的研究进展[J]. 肝癌电子杂志, 2021, 8(3): 41-45. |
[8] | 郑元文, 刘军. 肝癌肝移植术后预防复发的全程管理探讨[J]. 肝癌电子杂志, 2021, 8(3): 46-50. |
[9] | 付佐君, 刘贵生. 肝细胞癌早期诊断血清标志物研究进展[J]. 肝癌电子杂志, 2021, 8(3): 51-54. |
[10] | 李卓, 姜涛, 郎韧, 王苑. 1例胰腺神经内分泌肿瘤肝转移患者肝移植术后护理策略[J]. 肝癌电子杂志, 2021, 8(3): 59-61. |
[11] | 郑宣, 姜涛, 郞韧, 王维虎. 巨块型肝细胞癌合并门脉癌栓TACE联合放疗降期后肝移植长期生存1例[J]. 肝癌电子杂志, 2021, 8(3): 62-64. |
[12] | 吴杰, 高飞, 张雪松, 王魁阳, 隋成旭, 张亮, 姚远方, 宋磊. 半胱氨酸蛋白酶抑制SN在肝细胞癌中的表达意义[J]. 肝癌电子杂志, 2021, 8(2): 33-38. |
[13] | 黄小准, 王春玲, 黄璋侃, 徐林, 张仁杰, 毕新宇, 车旭, 赵建军. 切缘宽度影响肝细胞癌预后的临床研究进展[J]. 肝癌电子杂志, 2021, 8(2): 39-42. |
[14] | 于明华, 李威, 丁晓燕, 陈京龙. 乐伐替尼治疗晚期肝癌患者疗效的预测和预后因素研究进展[J]. 肝癌电子杂志, 2021, 8(2): 47-52. |
[15] | 黄桂荣, 吴德平, 陈方鹏, 韩山山. NRS-2002和CONUT评分与中晚期肝细胞癌患者预后分析及Nomogram模型构建[J]. 肝癌电子杂志, 2021, 8(2): 62-68. |
阅读次数 | ||||||
全文 |
|
|||||
摘要 |
|
|||||